CTIS2023-504376-21-00招募中1 期
A Phase 1b study to evaluate the safety, pharmacokinetics, and anti-tumour activity of the Myc inhibitor OMO-103 administered intravenously in combination with different drugs in patients with advanced solid tumours
Peptomyc S.L.0 个研究点目标入组 30 人开始时间: 2023年4月21日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
尚未招募
1 期
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Cavrotolimod in Subjects with Chronic Hepatitis B InfectioChronic Hepatitis B InfectionInfection - Other infectious diseasesACTRN12624000808549Bluejay Therapeutics, Inc40
尚未招募
1 期
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Cavrotolimod in Subjects with Chronic Hepatitis B InfectioChronic Hepatitis B InfectionInfection - Other infectious diseasesACTRN12624000809538Bluejay Therapeutics, Inc80
进行中（未招募）
1 期
Safety, pharmacokinetics, and preliminary efficacy of isatuximab in patients awaiting kidney transplantatio(Patients awaiting) kidney transplantationMedDRA version: 20.0Level: PTClassification code 10021425Term: Immune system disorderSystem Organ Class: 10021428 - Immune system disordersEUCTR2019-004154-28-ESSanofi-Aventis Recherche & Développement42
进行中（未招募）
1 期
A Study of Oleclumab (MEDI9447) with or without Durvalumab Combined with Chemotherapy in Subjects with Pancreatic CancerPancreatic Ductal AdenocarcinomaMedDRA version: 20.0Level: LLTClassification code 10051971Term: Pancreatic adenocarcinomaSystem Organ Class: 100000004864EUCTR2018-001028-21-ESMedImmune, LLC204
进行中（未招募）
1 期
A Study of Oleclumab (MEDI9447) with or without Durvalumab Combined with Chemotherapy in Subjects with Pancreatic CancerEUCTR2018-001028-21-NOMedImmune, LLC195